Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
63.02
UNCHANGED
Delayed Quote
Updated: 7:00 PM EST, Nov 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
73
74
Next >
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
↗
November 02, 2026
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
Via
The Motley Fool
Topics
Intellectual Property
MarketBeat Week in Review – 10/26 - 10/30
↗
October 31, 2026
Stocks wavered after the Fed held rates steady and Alphabet's earnings missed on Search revenue, fueling AI bubble concerns despite strong results from Microsoft and resilient earnings elsewhere.
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
Economy
5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings call
October 31, 2026
Bristol Myers Squibb’s third quarter results reflected robust growth in its core portfolio, led by strong commercial execution and momentum across newer prod...
Via
StockStory
Topics
Earnings
Bristol-Myers Squibb (NYSE:BMY) Posts Inline Q3 Revenue and 12% EPS Beat
↗
October 29, 2026
Via
Chartmill
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors
↗
October 26, 2026
Via
Chartmill
BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts
October 30, 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 6.9% year on yea...
Via
StockStory
Bristol Myers Squibb Q3 Earnings Call Highlights
↗
October 29, 2026
Bristol Myers Squibb (NYSE:BMY) raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a...
Via
MarketBeat
Topics
Earnings
Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
↗
October 29, 2026
Bristol Myers Squibb’s adjusted earnings fell 17%, but the company raised its sales outlook. Here’s why the drop reflects a pipeline refill, and what its newer drugs need to deliver next.
Via
The Motley Fool
Topics
Intellectual Property
Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript
↗
October 29, 2026
Eight growth medicines now each exceed $1 billion in annual sales.
Via
The Motley Fool
Topics
Earnings
Bristol-Myers Squibb’s (NYSE:BMY) Q3 2026 sales top estimates
October 29, 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.9% year on year to $13.07 bil...
Via
StockStory
3 Magnificent Dividend Stocks for Risk-Averse Investors
↗
October 28, 2026
Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.
Via
The Motley Fool
Bristol-Myers Squibb (BMY) Q3 earnings: what to expect
October 27, 2026
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what investors should kno...
Via
StockStory
Topics
Artificial Intelligence
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters
↗
October 27, 2026
The medication, which is being developed with the company's Chinese partner, did very well in a late-stage clinical trial.
Via
The Motley Fool
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation
↗
October 26, 2026
Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.
Via
The Motley Fool
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
↗
October 26, 2026
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.
Via
MarketBeat
Topics
Intellectual Property
Bristol Myers Squibb: Bargain Buy or Value Trap?
↗
October 26, 2026
The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.
Via
The Motley Fool
Topics
Intellectual Property
3 High-Yield Stocks to Buy With $1,000 Right Now
↗
October 26, 2026
These stocks pay yields far above the S&P 500's. And they keep raising their dividends.
Via
The Motley Fool
Topics
Intellectual Property
Stocks
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?
↗
October 25, 2026
Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.
Via
The Motley Fool
Topics
Intellectual Property
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
↗
October 23, 2026
One of these pharma stocks offers more income, but the other offers a safer dividend.
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
↗
October 22, 2026
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
Via
The Motley Fool
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
↗
October 22, 2026
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.
Via
The Motley Fool
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
↗
October 22, 2026
Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.
Via
The Motley Fool
Topics
Artificial Intelligence
Lawsuit
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
↗
October 21, 2026
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.
Via
The Motley Fool
Topics
Intellectual Property
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
↗
October 20, 2026
Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.
Via
The Motley Fool
S&P 500 Top Movers: Gainers and Losers From Today's US Session
↗
October 20, 2026
Via
Chartmill
Topics
Stocks
Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.
↗
October 20, 2026
Consider this pharma company's turnaround, not its dividend, its main appeal.
Via
The Motley Fool
Topics
Intellectual Property
3 Unpopular Stocks We Keep Off Our Radar
October 20, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via
StockStory
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
↗
October 18, 2026
It has been a volatile year for the biotech.
Via
The Motley Fool
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
↗
October 16, 2026
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.
Via
The Motley Fool
Topics
Intellectual Property
These S&P500 stocks are gapping in today's session
↗
October 15, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
73
74
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
